224 related articles for article (PubMed ID: 32286191)
21. FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.
Iravani A; Wallace R; Lo SN; Galligan A; Weppler AM; Hicks RJ; Sandhu S
Radiology; 2023 May; 307(3):e221180. PubMed ID: 36853183
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
23. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of pretreatment
Yang T; Liu S; Zuo R; Liang H; Xu L; Wang Z; Chen X; Pang H
BMC Med Imaging; 2023 Jan; 23(1):12. PubMed ID: 36681824
[TBL] [Abstract][Full Text] [Related]
26. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
27. TAC y PET/TC con 18-FDG para evaluar la respuesta al tratamiento en linfoma de Hodgkin y no Hodgkin.
Vargas-Partida T; Hernández-Cruz M; Ruiz-Eng R; Montiel-Jarquín ÁJ; Vázquez-Cruz E; López-Colombo A
Gac Med Mex; 2019; 155(4):386-390. PubMed ID: 31486785
[TBL] [Abstract][Full Text] [Related]
28. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.
Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
Leuk Lymphoma; 2007 Aug; 48(8):1539-47. PubMed ID: 17701585
[TBL] [Abstract][Full Text] [Related]
29. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Lamonica D; Graf DA; Munteanu MC; Czuczman MS
J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
33. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
35.
Eisazadeh R; Mirshahvalad SA
Clin Imaging; 2022 Dec; 92():25-31. PubMed ID: 36179394
[TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
37. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
